GenSight Biologics S.A.

Dallas, TX-based Nanoscope Therapeutics has begun a rolling US submission for a gene therapy to treat retinitis pigmentosa that it hopes will potentially target a broader patient population than most

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

With the US Inflation Reduction Act threatening a major shake-up in drug pricing from 2023 onwards, and with the progress of increasing numbers of costly advanced therapeutics onto the market, one thi

Paris, France-based biotech HORAMA is relaunching itself as Coave Therapeutics, and a €33.1m ($39m) series B fundraising to help accelerate its progress in the competitive world of gene therapy. The